Intermittent fasting (IF) is associated with measurable weight loss and metabolic benefits in adults with overweight or obesity, researchers reported in JAMA Network Open. The investigators conducted an “umbrella” review of several other meta-analyses of randomized clinical trials (RCTs) to more specifically define the benefits associated with IF on obesity-related health outcomes.
PubMed, Embase, and the Cochrane database were searched from inception to January 12, 2021 to identify relevant meta-analyses of RCTs involving IF. The Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria were used to assess the quality of evidence per effect. he study authors selected 11 meta-analyses, which included 130 RCTs (45 unique RCTs) with a median (interquartile range [IQR]) sample size per RCT of 38 (24-69 participants) studies and follow-up of 3 (2-5) months. A total of 104 unique associations were identified, with a median (IQR) of 4 (3-5) studies per association and median IQR sample size of 266 (119-423) participants.
Excerpted from Endocrinology Advisor